account_id none on file
legal_name Sutro Biopharma, Inc.
ticker STRO
cik 1382101
domain sutrobio.com
linkedin_company_url https://www.linkedin.com/company/sutro-biopharma-inc./
entry_point_account_id none on file
name Sutro Biopharma Inc.
exchange Nasdaq
sector Health Care
hq South San Francisco, CA, United States
sector index/company/sector/health-care/
calls 0 filings 8 executives 0 family 0
why_nownone on file
callsnone on file
filings
In March 2025, our Board of Directors approved a strategic portfolio review, or the March 2025 Restructuring Plan, with an associated planned reduction in our workforce, as a result of its review of current strategic priorities, resource allocation, and cost reduction intended to reduce operating costs, streamline operations and extend our cash runway.
filing / Aug 12, 2026 / receipt
In September 2025, we announced a further reduction in our workforce of approximately one third of our remaining employees, or the September 2025 Restructuring Plan, and, together with the March 2025 Restructuring Plan, the Restructuring Plans, which was intended to further reduce operating costs, streamline operations, and extend our cash runway.
filing / Aug 12, 2026 / receipt
In connection with this March 2025 Restructuring Plan, we deprioritized further investment in our late stage clinical development product candidate, luveltamab tazevibulin, which development has been terminated, and refocused our activities on our clinical and preclinical pipeline, including STRO-004, STRO-227, and STRO-006.
filing / Aug 12, 2026 / receipt
In March 2025, we announced the March 2025 Restructuring Plan resulting in the prioritization of our three wholly-owned preclinical programs in our next-generation ADC pipeline.
filing / Aug 12, 2026 / receipt
In March 2025, our Board of Directors approved a strategic portfolio review, or the March 2025 Restructuring Plan, with an associated planned reduction in our workforce, as a result of its review of current strategic priorities, resource allocation, and cost reduction intended to reduce operating costs, streamline operations and extend our cash runway.
filing / May 14, 2026 / receipt
In September 2025, we announced a further reduction in our workforce of approximately one third of our remaining employees, or the September 2025 Restructuring Plan, and, together with the March 2025 Restructuring Plan, the Restructuring Plans, which was intended to further reduce operating costs, streamline operations, and extend our cash runway.
filing / May 14, 2026 / receipt
In connection with this March 2025 Restructuring Plan, we deprioritized further investment in our late stage clinical development product candidate, luveltamab tazevibulin, which development has been terminated, and refocused our activities on our clinical and preclinical pipeline, including STRO-004, STRO-227, and STRO-006.
filing / May 14, 2026 / receipt
In March 2025, we announced the March 2025 Restructuring Plan resulting in the prioritization of our three wholly-owned preclinical programs in our next-generation ADC pipeline.
filing / May 14, 2026 / receipt
executivesnone on file
familynone on file
upcoming
| 2026-11-05 | earnings call | scheduled | ir |
changesnone on file
mcp_package_hint
slug sutro-biopharma-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$